Found: 6
Select item for more details and to access through your institution.
Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies.
- Published in:
- BMC Endocrine Disorders, 2021, v. 21, n. 1, p. 1, doi. 10.1186/s12902-021-00797-4
- By:
- Publication type:
- Article
Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL‐1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 4, p. 521, doi. 10.1111/dom.13919
- By:
- Publication type:
- Article
Efficacy and safety of MYL‐1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 3, p. 365, doi. 10.1111/dom.13904
- By:
- Publication type:
- Article
Efficacy and safety of MYL‐1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 1, p. 129, doi. 10.1111/dom.13495
- By:
- Publication type:
- Article
New Fixed-Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High-Risk Patients with Mixed Dyslipidemia Versus Monotherapies.
- Published in:
- Cardiovascular Therapeutics, 2015, v. 33, n. 6, p. 329, doi. 10.1111/1755-5922.12148
- By:
- Publication type:
- Article
Pharmacokinetic interaction between simvastatin and fenofibrate with staggered and simultaneous dosing: Does it matter?
- Published in:
- Journal of Clinical Pharmacology, 2014, v. 54, n. 9, p. 1038, doi. 10.1002/jcph.291
- By:
- Publication type:
- Article